Gensci Showcases Women's Health and Immunology Innovations at BIO 2025
Time
2025-06-18
Readership
1462
Share
Gensci showcased its key innovative pipelines at BIO International Convention 2025 through our Head of R&D BD and License-out, Dr. Yuanfeng Xia. The presentation highlighted the women's health project Gensci074 and the immunology asset GenSci120.
The NK3R antagonist Gensci074, for treating moderate-to-severe vasomotor symptoms (VMS) in menopausal women, showed excellent progress. It completed final patient enrollment for its China Phase II study in January 2025. Clinical data revealed significant reductions in hot flash frequency and severity compared to placebo at weeks 4 and 12. Importantly, no liver enzyme elevation risks were observed. Gensci074 demonstrated superior preclinical and clinical (Phase I PK/PD and Phase II POC) data , positioning it as a potential "Best-in-class" VMS treatment. This breakthrough addresses a major unmet need – approximately 880 million perimenopausal women worldwide suffer from VMS.
Dr. Yuanfeng Xia is presenting the innovative assets
Gensci has established a comprehensive strategy in women's health,covering reproductive health,gynecological infections, common diseases, and gynecological cancers. The approach combines BD partnerships with over 10 R&D pipelines. Key targets include bacterial vaginosis, menopausal VMS, endometriosis, and long-acting formulations for fertility treatments. Significant progress was also reported on two other assets:
· GenSci098, a TSHR inhibitor for Thyroid Eye Disease (TED), showed rapid, durable efficacy and good safety in Phase I.
· GenSci120, a humanized PD-1 monoclonal antibody, treats autoimmune diseases like rheumatoid arthritis (RA). It works by activating the PD-1 inhibitory pathway and ADCC effects. This asset has received clinical trial approvals in both China and the US.
Gensci's outcomes show its commitment to becoming a global leader in women's and children's health. Gensci will continue accelerating the development of safe and effective innovative therapies focused on patient needs.
